October 19 2023, Shanghai, China — Roche Pharmaceutical (hereinafter referred to as “Roche”) and Alebund Pharmaceuticals (hereinafter referred to as “Alebund”) entered a supply and marketing agreement, under which Alebund will exclusively promote Roche’s MIRCERA® (methoxy polyethylene glycol-epoetin beta) in mainland China.
Continue reading Alebund Reached Cooperation with Roche to Commercialize MIRCERA® In ChinaAlebund Pharmaceuticals and Peking University First Hospital enter into a strategic partnership to develop a novel and specific treatment for IgA Nephropathy (IgAN)
SHANGHAI/BEIJING, CHINA, June 30, 2022 — Alebund Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced a strategic partnership between its subsidiary Alezyme and Peking University First Hospital, to discover, develop and commercialize PKU308/AP308, a potential innovative and specific therapeutic for IgAN. Designed and developed by Peking University First Hospital, this compound has a completely innovative mechanism of action (MOA) as compared to currently available treatment options.
Continue reading Alebund Pharmaceuticals and Peking University First Hospital enter into a strategic partnership to develop a novel and specific treatment for IgA Nephropathy (IgAN)Chugai and Alebund Enter into Option and License Agreement for EOS789 under Development for Hyperphosphatemia
Chugai Pharmaceutical Co., Ltd.
Alebund Pharmaceuticals (Hong Kong) Limited
- Chugai and Alebund enter into an option and license agreement regarding EOS789, an investigational drug for hyperphosphatemia, discovered by Chugai
- If Alebund decides to exercise the option, Chugai will grant to Alebund an exclusive license to develop, manufacture, and commercialize EOS789 worldwide including Japan
TOKYO, JAPAN and SHANGHAI, CHINA, July 9, 2021 — Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and Alebund Pharmaceuticals (Hong Kong) Limited, announced that they have entered into an option and license agreement regarding Chugai’s EOS789, an investigational agent under development for hyperphosphatemia.
Continue reading Chugai and Alebund Enter into Option and License Agreement for EOS789 under Development for Hyperphosphatemia